Equillium to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Equillium (Nasdaq: EQ) announced management will participate in two investor conferences in early December 2025: the Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 11:30 AM ET and the Evercore ISI 8th Annual Healthcare Conference on Dec 3, 2025 at 3:50 PM ET. Meetings will include fireside chats and 1x1 investor meetings.

Management is available for meetings with registered investors. Investors are invited to review the company corporate deck on the Events & Presentations page and the replay of the recent virtual KOL event discussing EQ504, an aryl hydrocarbon receptor modulator for ulcerative colitis.

News Market Reaction

%

12 alerts

% News Effect

+7.8% Peak Tracked

-2.8% Trough Tracked

$72M Market Cap

0.6x Rel. Volume

On the day this news was published, EQ declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Piper Sandler 37th Annual Healthcare Conference
Format:	Fireside Chat & 1x1 Meetings
Date:	Tuesday, December 2, 2025
Time:	11:30 AM EST

Evercore ISI 8th Annual Healthcare Conference
Format:	Fireside Chat & 1x1 Meetings
Date:	Wednesday, December 3, 2025
Time:	3:50 PM EST

Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

Investors are invited to review the company corporate deck found on the Events & Presentations page, as well as the replay from the recent virtual KOL Event to discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit www.equilliumbio.com.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

FAQ

When will Equillium (EQ) present at the Piper Sandler Healthcare Conference?

Equillium management will present on December 2, 2025 at 11:30 AM ET with a fireside chat and 1x1 meetings.

When is Equillium (EQ) scheduled to participate at the Evercore ISI Healthcare Conference?

Equillium management will participate on December 3, 2025 at 3:50 PM ET including a fireside chat and 1x1 meetings.

How can investors request meetings with Equillium (EQ) at these conferences?

Investors registered for the conferences can request meetings directly with Equillium management; availability is for registered attendees only.

Where can investors find Equillium's (EQ) corporate deck and related materials ahead of the conferences?

The corporate deck is available on the company's Events & Presentations page on its investor website.

What recent program will Equillium (EQ) discuss in the conference materials and replay?

The company provided a replay of a virtual KOL event discussing EQ504, an AhR modulator under development for ulcerative colitis.